Program
ratutrelvir
Also written as “Ratutrelvir (83-0060) non-randomised”, “Ratutrelvir (83-0060)” and “83-0060”.
Its studies are mostly in COVID-19, led by Traws Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Traws Pharma | 20 open or running | phase 2since Sep 3, 2025 | May 2, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- May 2, 2024First study: phase 1 study in Healthy Volunteers OnlyFirst studyNCT06402136 · 57 enrolled · Australia
- Feb 13, 2025Named ratutrelvirINNProposed as its International Nonproprietary Name in WHO's List 132
- Sep 3, 2025Phase 2 study in COVID-19NCT07157007 · 93 enrolled · Uzbekistan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07157007COVID-19 · Uzbekistan | 2 | Completed | Feb 16, 2026 | 93 |
| NCT06402136Healthy Volunteers Only · Australia | 1 | Completed | Aug 9, 2024 | 57 |
How it is read
Names in the registry
- “Ratutrelvir (83-0060) non-randomised”, 1 entry
- “Ratutrelvir (83-0060)”, 1 entry
- “83-0060”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.